worldpharmanewsMarch 29, 2017
Tag: AstraZeneca
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present the strength and depth of its translational science, which is expected to deliver the Company's next wave of innovative oncology medicines, at the American Association for Cancer Research (AACR) Annual Meeting in Washington DC, US, 1-5 April 2017.
In addition to demonstrating a robust early oncology portfolio in DNA Damage Response (DDR) and Tumour Drivers and Resistance, AstraZeneca will highlight the continued progress being made in early Immuno-Oncology (IO) and Antibody-Drug Conjugate (ADC) science.
Susan Galbraith, Senior Vice President, Head of Oncology, Innovative Medicines and Early Development (IMED) Biotech Unit, said: "The progress we will report at AACR 2017 highlights the rapid growth of our highly-differentiated DNA Damage Response portfolio that targets a broad range of key molecular pathways. Presentations will also show our progress within Tumour Drivers and Resistance with the development of molecules targeting two key mechanisms that tumours use to resist cell death, namely MCL-1 and CDK9."
David Berman, Senior Vice President, Head of Oncology Innovative Medicines at MedImmune, added: "AACR 2017 is an exciting moment for our next-generation oncology portfolio, demonstrating how our broad biologics pipeline is targeting the multiple ways cancer evades the immune system. We will update on our scientific progress in cancer Immuno-Oncology, including predictive biomarkers of response to immune checkpoint inhibitors. We also look forward to presenting the first clinical trial results for our TLR 7/8 agonist, an important mechanism for immunologically-silent tumours, and to sharing updates from our Antibody-Drug Conjugate platform, a key pillar of AstraZeneca’s oncology strategy."
Shedding new light on Tumour Drivers and Resistance
AstraZeneca was a pioneer in the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for patients with non-small cell lung cancer (NSCLC) (Iressa, Tagrisso), and continues to work on the unmet needs of patients who fail to respond, or respond for limited periods, to these compounds. An expanding programme of tumour cell-death research is targeting upregulation of key proteins that cancer cells use to evade death, including myeloid cell leukaemia 1 (MCL-1) and cyclin-dependent kinase 9 (CDK9) and is leveraging the sophistication of macrocyles - larger, cyclic compounds - to address the complexity of protein interactions.
Presentations include:
A leading DNA Damage Response (DDR) position
With one approved medicine and four candidates in clinical development, AstraZeneca is extending its leadership in medicines that target novel DDR deficiencies to selectively kill cancer cells, while minimising the impact on normal cells.
Four oral presentations will include the following data:
Preliminary results will also be reported from a Phase I dose-escalation study of the ataxia-telangiectasia and Rad3 related (ATR) inhibitor, AZD6738, in advanced solid tumours (PATRIOT Part A) (Abstract #CT084).
Immuno-Oncology (IO): Activating the immune system via multiple approaches
Presentations will illustrate the depth of AstraZeneca's IO capabilities beyond its comprehensive late-stage portfolio.
Key presentations include:
Antibody-Drug Conjugates: Sophisticated targeting of toxic payloads
AstraZeneca will share data demonstrating the potential of a range of ADCs in targeting cytotoxic treatments to tumour cells. These include preclinical data with toxic pyrrolobenzodiazepine (PBD) or tubulysin payloads in combination with multiple immunotherapies (Abstract #4596), and data on the potent anti-tumour activity of ADCT-401/MEDI3726 when targeting prostate-specific membrane antigen (PSMA) in prostate cancer models (Abstract #3111A).
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca's six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms - Immuno-Oncology, the genetic drivers of cancer and resistance, DNA Damage Response and Antibody-Drug Conjugates - and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology; Respiratory, Cardiovascular & Metabolic Diseases; and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK, and Mountain View, CA.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: